| Richard C.Ahrens, M.D. |
| Professor of Pediatrics |
| Email: richard-ahrens@uiowa.edu |
| Phone: (319) 356-4050 |
| EHSRC Role(s): |
Member, Environmental Lung Disease Research Cluster |
Dr. Ahrens has significant experience in the clinical pharmacology of asthma and cystic fibrosis, and in the clinical care of patients with lung disease. Primary focuses have been the development of novel study designs to meet challenges in the pharmacologic management of pulmonary disease, and in vivo and in vitro assessment of aerosol drug delivery. He has experience in clinical trials for asthma, including bioassay quantification of pulmonary deposition and activity of inhaled beta adrenergic and corticosteroid agents.
Dr. Ahrens began shifting his focus to CF clinical investigation four years ago. He has training in Pediatrics, Pediatric Pulmonary Disease, and Clinical Pharmacology, and is Co-Director of the CF Clinical Center. Dr. Ahrens' clinical research pertains to the development of methods for identifying and quantitating early lung injury in CF.
Recent Publications
- Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC Guyatt G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. American College of Chest Physicians / American College of Asthma, Allergy and Immunology. Chest 127:335-371, 2005.
- Chrischilles E, Ahrens R, Kuehl A, Kelly K, Thorne P, Burmeister L, Merchant J. Asthma prevalence and morbidity among rural Iowa schoolchildren. J Allergy Clin Immunol 113:66-71, 2004.
- Hendeles L, Beaty R, Ahrens R, Stevens G, Harman EM. Response to inhaled albuterol during nocturnal asthma. J Allergy Clin Immunol 113:1058-1062, 2004.
- Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol Published Online: 30 Nov 2004; DOI: 10.1002/ppul.20152.
- Ahrens RC, Standaert TA, Launspach J, Han S-H, Teresi M, Aitken ML, Kelly TJ, Hilliard K, Milgram L, Konstan M, McCarty N. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 33(2):142-150, 2002.
- McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelly TJ, Milgram L, Hilliard K, Weatherly MR, Aitken ML, Konstan M, Ahrens RC. A phase I randomized, multicenter trial of CPX in adult patients with mild cystic fibrosis. Pediatr Pulmonol 33(2):90-98, 2002.
- Ahrens RC, Aitken ML, Konstan MW, McCarty NA. Letters to the Editor. The Authors Reply. Pediatr Pulmonol 34(2):156, 2002.
- Asmus MJ, Stewart BA, Milavetz G, Teresi ME, Han S-H, Wong D, Ahrens RC. Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers. Pharmacotherapy 22(5):557-563, 2002.
|
